• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)
Introduction The world is undergoing a demographic transition to an older population. Preventive healthcare has reduced the burden of chronic illness at younger ages but there is limited evidence that these advances can improve health at older ages. Statins are one class of drug with the potential to prevent or delay the onset of several causes of incapacity in older age, particularly major cardiovascular disease (CVD). This paper presents the protocol for the STAtins in Reducing Events in the Elderly (STAREE) trial, a randomised double-blind placebo-controlled trial examining the effects of statins in community dwelling o...
Source: BMJ Open - April 3, 2023 Category: General Medicine Authors: Zoungas, S., Curtis, A., Spark, S., Wolfe, R., McNeil, J. J., Beilin, L., Chong, T. T.-J., Cloud, G., Hopper, I., Kost, A., Nelson, M., Nicholls, S. J., Reid, C. M., Ryan, J., Tonkin, A., Ward, S. A., Wierzbicki, A., On behalf of STAREE investigator group Tags: Open access, Cardiovascular medicine Source Type: research

Patient suitability for free water protocols in acute stroke and general medicine: a qualitative study of clinician perceptions
CONCLUSIONS & IMPLICATIONS: Despite the benefits of FWPs in other settings, in acute stroke and general medicine, clinicians erred on the side of safety and, in most cases, would not implement an FWP. Future clinical research is needed to systematically design high-quality and feasible clinical trials to determine the benefits and safety of FWPs for patients with dysphagia in these settings. This would lay the foundations for guidelines to support the complex clinical decision-making regarding patient suitability for FWPs.WHAT THIS PAPER ADDS: What is already known on the subject FWPs are an alternate management strategy f...
Source: International Journal of Language and Communication Disorders - March 23, 2022 Category: Speech-Language Pathology Authors: Joanne Murray Shannon Maloney Kaitlyn Underdown Sebastian Doeltgen Source Type: research

Psychometric properties of the EQ-5D-3L in South Australia: a multi-method non-preference-based validation study
This study aims to psychometrically validate the EQ-5D-3L in a large population sample in Australia for the first time.METHODS: The EQ-5D-3L was included in the Dental Care and Oral Health study (DCOHS), conducted in a South Australian population sample. The participants were 23-91 years old, and 44.1% were male. The EQ-5D-3L was responded to on a three-point rating scale ("none"/"no", "some" and "extremely"/"unable"/"confined"). We employed the area under the receiver operating characteristic curve (AUROC) to evaluate whether the EQ-5D-3L total score could identify participants with diagnosed diseases and mental health di...
Source: Current Medical Research and Opinion - January 21, 2022 Category: Research Authors: Mehrsa Zakershahrak Pedro H Ribeiro Santiago Sneha Sethi Dandara Haag Lisa Jamieson David Brennan Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cardioprotective Activity of Agaricus bisporus Against Isoproterenol- Induced Myocardial Infarction in Laboratory Animals
Conclusion: It can be an outcome that EEAB possessed cardioprotective activity against experimental and clinical studies of ISO-induced myocardial infarction in rats.
Source: Current Nutrition and Food Science - June 28, 2019 Category: Nutrition Source Type: research

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions
ConclusionReclassifying OCPs is likely to be considered cost effective by Australian decision makers.
Source: PharmacoEconomics - May 8, 2019 Category: Health Management Source Type: research

5 Trends Medtech Should Be Talking About
Recently I chatted with Candace Roulo, managing editor of Advanced Manufacturing Now, about some of the most important trends in medtech and the technologies that are taking the industry to the next level. Click below to listen to the podcast, or read on for select highlights of the conversation – what I consider to be five trends medtech professionals should be talking about. 128-Advanced_Manufacturing_Now-UBM.mp3 Explore all of these trends in depth at the BIOMEDevice Boston Conference and Expo, April 18-19, 2018. Use promo code "SAVE100" for $100 off conference registration and free expo access.   1. Muc...
Source: MDDI - April 6, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: BIOMEDevice Boston Business Digital Health Source Type: news

Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey
ConclusionThe study identified knowledge gaps in patients taking OACs, and these deficiencies appeared to be greater in participants taking DOACs. Knowledge assessment should be integrated into patient counselling sessions to help identify and resolve knowledge deficits.
Source: International Journal of Clinical Practice - January 1, 2018 Category: Internal Medicine Authors: Kehinde O. Obamiro, Leanne Chalmers, Kenneth Lee, Bonnie J. Bereznicki, Luke R. E. Bereznicki Tags: ORIGINAL PAPER Source Type: research